Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Immuneering (IMRX) Shares Outstanding (2020 - 2026)

Immuneering's Shares Outstanding history spans 7 years, with the latest figure at $64.7 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding rose 79.76% to $64.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $64.7 million, a 79.76% increase, with the full-year FY2025 number at $64.6 million, changed N/A from a year prior.
  • Shares Outstanding came in at $64.7 million for Q1 2026, up from $63.5 million in the prior quarter.
  • The five-year high for Shares Outstanding was $64.7 million in Q1 2026, with the low at $26.4 million in Q1 2022.
  • Historically, Shares Outstanding has averaged $34.7 million across 5 years, with a median of $29.5 million in 2023.
  • Peak annual rise in Shares Outstanding hit 400.24% in 2022, while the deepest fall reached 0.37% in 2022.
  • Year by year, Shares Outstanding stood at $26.4 million in 2022, then increased by 10.79% to $29.3 million in 2023, then grew by 6.09% to $31.1 million in 2024, then skyrocketed by 108.2% to $64.6 million in 2025, then increased by 0.06% to $64.7 million in 2026.
  • Business Quant data shows Shares Outstanding for IMRX at $64.7 million in Q1 2026, $64.6 million in Q4 2025, and $36.0 million in Q2 2025.